$PYPD News

This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026

PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026

PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data

European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀

PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities

PolyPid Agrees With ADVANZ PHARMA To Terminate Their 2022 Exclusive License, Distribution And Supply Agreement For D-PLEX₁₀₀ In Europe

PolyPid Announces Participation in Upcoming Fall Investor Conferences

PolyPid (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ...

PolyPid Ltd. Q2 2026 Earnings Call Summary

PolyPid Q2 Earnings Call Highlights

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid Q2 EPS $(0.35) Beats $(0.38) Estimate

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28

Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid

HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target